About Ablexis
Ablexis is a company based in San Francisco (United States) founded in 2009 was acquired by Deerfield in June 2018.. Ablexis has raised $12 million across 1 funding round from investors including Third Rock Ventures, Pfizer Venture Investments and Deerfield. Ablexis offers products and services including Transgenic Mouse Platform. Ablexis operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ablexis, Llc
- Jurisdiction Bangalore North, Karnataka, India
-
Annual Revenue
$403.09 K (USD)19.31as on Mar 31, 2022
-
Net Profit
$26.11 K (USD)-14.87as on Mar 31, 2022
-
EBITDA
$31.2 K (USD)28.43as on Mar 31, 2022
-
Total Equity Funding
$12 M (USD)
in 1 rounds
-
Latest Funding Round
$12 M (USD), Series A
Jun 02, 2010
-
Investors
Third Rock Ventures
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Deerfield
(Jun 21, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ablexis
Ablexis offers a comprehensive portfolio of products and services, including Transgenic Mouse Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for discovering and developing therapeutic antibody candidates efficiently.
Unlock access to complete
Unlock access to complete
Funding Insights of Ablexis
Ablexis has successfully raised a total of $12M through 1 strategic funding round. The most recent funding activity was a Series A round of $12 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $12.0M
-
First Round
First Round
(02 Jun 2010)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2010 | Amount | Series A - Ablexis | Valuation | Third Rock Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ablexis
Ablexis has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Third Rock Ventures, Pfizer Venture Investments and Deerfield. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to early-stage life science companies.
|
Founded Year | Domain | Location | |
|
Venture capital is focused on healthcare by Pfizer's investment arm.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ablexis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ablexis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ablexis Comparisons
Competitors of Ablexis
Ablexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ablexis
Frequently Asked Questions about Ablexis
When was Ablexis founded?
Ablexis was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Where is Ablexis located?
Ablexis is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Ablexis a funded company?
Ablexis is a funded company, having raised a total of $12M across 1 funding round to date. The company's 1st funding round was a Series A of $12M, raised on Jun 02, 2010.
What is the annual revenue of Ablexis?
Annual revenue of Ablexis is $403.09K as on Mar 31, 2022.
What does Ablexis do?
Ablexis was founded in 2009 in San Francisco, United States, within the biotechnology sector focused on antibody development. Transgenic mouse platforms are created by the company to support human antibody drug discovery and development. The AlivaMab Mouse platform was acquired from Aliva Biopharmaceuticals, featuring immunoglobulin loci designed for efficient function in these processes. In 2010, a consortium was formed, licensing the technology to five leading global biopharmaceutical firms, including Pfizer.
Who are the top competitors of Ablexis?
Ablexis's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Ablexis offer?
Ablexis offers Transgenic Mouse Platform.
Who are Ablexis's investors?
Ablexis has 3 investors. Key investors include Third Rock Ventures, Pfizer Venture Investments, and Deerfield.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.